Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Hyperbaric oxygen therapy augments tobramycin efficacy in experimental Staphylococcus aureus endocarditis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Azithromycin potentiates avian IgY effect against Pseudomonas aeruginosa in a murine pulmonary infection model

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Efficacy of mecillinam against clinical multidrug-resistant Escherichia coli in a murine urinary tract infection model

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Hot topics on procalcitonin use in clinical practice, can it help antibiotic stewardship?

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming

    Research output: Contribution to journalLetterResearchpeer-review

  2. Risk Factors for Being Seronegative following SARS-CoV-2 Infection in a Large Cohort of Health Care Workers in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Associations between YKL-40 and markers of disease severity and death in patients with necrotizing soft-tissue infection

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Staphylococcus aureus infective endocarditis (IE) is a serious disease with an in-hospital mortality of up to 40%. Improvements in the effects of antibiotics and host responses could potentially benefit outcomes. Hyperbaric oxygen therapy (HBOT) represents an adjunctive therapeutic option. In this study, the efficacy of HBOT in combination with tobramycin in S. aureus IE was evaluated. A rat model of S. aureus IE mimicking the bacterial load in humans was used. Infected rats treated subcutaneously with tobramycin were randomised into two groups: (i) HBOT twice daily (n = 13); or (ii) normobaric air breathing (non-HBOT) (n = 17). Quantitative bacteriology, cytokine expression, valve vegetation size and clinical status were assessed 4 days post-infection. Adjunctive HBOT reduced the bacterial load in the aortic valves, myocardium and spleen compared with the non-HBOT group (P = 0.004, <0.001 and 0.01, respectively) and improved the clinical score (P <0.0001). Photoplanimetric analysis and weight of valve vegetations showed significantly reduced vegetations in the HBOT group (P <0.001). Key pro-inflammatory cytokines [IL-1β, IL-6, keratinocyte-derived chemokine (KC) and vascular endothelial growth factor (VEGF)] were significantly reduced in valves from the HBOT group compared with the non-HBOT group. In conclusion, HBOT augmented tobramycin efficacy as assessed by several parameters. These findings suggest the potential use of adjunctive therapy in severe S. aureus IE.

Original languageEnglish
JournalInternational Journal of Antimicrobial Agents
Volume50
Issue number3
Pages (from-to)406-412
Number of pages7
ISSN0924-8579
DOIs
Publication statusPublished - Sep 2017

    Research areas

  • Journal Article

ID: 51804709